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Background: The benefits of primary tumor downstaging and assessment of chemoresponsive-
ness have resulted in expanded applications for induction chemotherapy. However, the pathologic
evaluation and prognostic significance of response in preoperatively treated lymph nodes have not
been defined.
Methods: The axillary lymph nodes of 71 patients with locally advanced breast cancer treated
with induction chemotherapy were evaluated for histological evidence of tumor regression as
defined by the presence of nodal fibrosis, mucin pools, or aggregates of foamy histiocytes.
Results: Complete pathologic response in the breast and axilla occurred in 10 patients (14%); 19
(26.8%) had evidence of tumor regression in 1 or more lymph nodes. Patients without nodal
metastases and no evidence of tumor regression had the best outcome (median disease-free survival,
31.5 months; relapse rate, 27%). Patients with residual nodal metastases and no evidence of
treatment effect had the worst outcome (median disease-free survival, 19.8 months; relapse rate,
55%). The median disease-free survival was 22.1 months, and the relapse rate was 32% for patients
with histopathologic evidence of tumor regression in the axillary lymph nodes.
Conclusions: Detection of treatment effect in axillary lymph nodes after induction chemotherapy
identifies a subset of patients with an outcome intermediate between that of completely node-
negative and node-positive patients. The axillary lymph nodes of patients receiving preoperative
chemotherapy should be routinely analyzed for the presence of these features.
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Induction chemotherapy (CTX) is standard management
for patients with locally advanced breast cancer. The ben-
efits of tumor downstaging and the ability to assess tumor
response to CTX in vivo have resulted in expanded appli-
cations of this treatment approach to patients with early-
stage, resectable disease.1–6 CTX can sterilize axillary
nodal metastases in 25% to 30% of cases,4,7 and the extent
of nodal disease retains prognostic value.8
However, pathologic assessment of the CTX effect on
nodal metastases is poorly understood. Improved meth-
ods of evaluating lymph nodes in patients receiving
preoperative CTX will facilitate the integration of lym-
phatic mapping into induction CTX protocols. The goal
of this study was to correlate a predetermined profile of
nodal CTX response features with outcome in a series of
patients with locally advanced breast cancer.
METHODS
Histopathologic findings from surgical specimens of
71 patients with locally advanced breast cancer (stages
IIB, IIIA, IIB and IV; limited or supraclavicular metas-
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tases) treated with preoperative CTX were evaluated.
The study patients were treated between 1993 and 1999,
and CTX regimens included doxorubicin in all patients.
A standard level I/II axillary lymph node dissection was
performed in all cases, and all patients received postop-
erative chest radiotherapy. Axillary lymph nodes were
studied for evidence of metastases by serial sectioning
and hematoxylin and eosin staining.
Evidence of tumor regression, or response to induction
CTX, within an axillary lymph node was defined as the
presence of nodal fibrosis, mucin pools, or large aggre-
gates of foamy histiocytes. An example of nodal fibrosis
and mucinous changes is shown in Fig. 1.
Statistical analysis was conducted with the t-test for
continuous variables and the 2 test for discrete vari-
ables. Survival was evaluated with the Kaplan-Meier
method. Median follow-up was 29 months.
RESULTS
Clinical characteristics of the study population are
listed in Table 1. The median patient age was 51 years.
Most patients had invasive ductal carcinomas. Slightly
more than half of all patients had T4 tumors, and more
three quarters had either N1 or N2 disease at
presentation.
Pathologic response findings are listed in Table 2. A
complete pathologic response (no residual invasive dis-
ease in the breast specimen or in axillary lymph nodes)
occurred in 10 patients (14%); one of these patients had
residual ductal carcinoma-in-situ in the breast tissue.
Assessment of response to CTX in axillary lymph nodes
revealed 12 patients with no axillary nodal disease and
no evidence of prior nodal metastases that had responded
to treatment. A total of 19 patients (27%) had histolog-
ical evidence of tumor regression in axillary lymph
nodes; 9 of these patients also had residual viable lymph
node metastases, and 10 had no evidence of viable axil-
lary metastases.
As shown in Table 3, only tumor category at presen-
tation was a statistically significant predictor of treat-
ment failure. Twenty-seven percent of patients with T3
tumors at presentation experienced disease relapse, com-
pared with 57.9% of patients with T4 tumors.
For the survival analysis, the patients with evidence of
disease response in axillary lymph nodes were consid-
ered together in one group, regardless of whether or not
TABLE 2. Pathologic findings in breast and axillary





Complete response (no residual invasive disease; axillary
lymph nodes negative)
10 (14.1)
Partial response (50% decrease in primary tumor size) 53 (74.6)
No response/stable disease (50% decrease in primary
tumor size)
8 (11.3)
Axillary nodal pathology findingsa
No axillary metastases; no evidence of nodal tumor
regression
12 (16.9)
No axillary metastases; positive evidence of nodal
tumor regression
10 (14.1)
Positive axillary metastases; positive evidence of nodal
tumor regression
9 (12.7)
Positive axillary metastases; no evidence of nodal
tumor regression
39 (54.9)
a Data are missing on one patient.
FIG. 1. Histopathology patterns of fibrosis and mucinous changes
consistent with a treatment effect in the lymph node of a breast cancer
patient.
TABLE 1. Clinical characteristics of the study patient
population (N  71 patients)
Feature Data

















Invasive ductal 69 (97%)
Invasive lobular 2 (3%)
AJCC, American Joint Committee on Cancer, Fifth Edition.
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viable metastases were also present. These subsets were
considered together because of the small sample size
(nine patients) of cases with the mixed pattern of tumor
regression in the presence of residual metastases. Re-
lapse rates and median disease-free survival times for the
remaining patient subsets based on axillary pathology
findings are listed in Table 4. The small sample sizes
preclude meaningful statistical testing, but a trend was
seen for improved outcome in the subsets of patients who
either were completely node negative or seemed to have
been downstaged to node negativity because of a treat-
ment effect on axillary metastases, compared with the
subset of patients who had residual viable axillary me-
tastases. However, the subset of downstaged node-neg-
ative patients had a higher relapse rate and shorter dis-
ease-free survival compared with the completely node-
negative patients.
DISCUSSION
History of Induction CTX: Locally Advanced
Breast Cancer
Primary CTX followed by definitive breast and axil-
lary is now well established as standard management for
patients with locally advanced breast cancer.1,9 Initial
reservations regarding this treatment sequence were
based on concerns that delayed surgery might result in
increased surgical morbidity and loss of a “window of
opportunity” to obtain durable locoregional disease con-
trol with surgical intervention. These concerns regarding
the surgical management of locally advanced disease
have been largely answered by studies demonstrating
that approximately 80% of patients will experience sig-
nificant shrinkage of their breast tumors in response to
primary CTX, thereby facilitating subsequent surgery. In
contrast, only 2% to 3% of patients will exhibit progres-
sive disease. Furthermore, studies of preoperative versus
postoperative CTX for locally advanced breast cancer
patients have demonstrated that surgical complication
rates are unaffected by the neoadjuvant CTX sequence.10
An additional area of concern has been the issue of
preoperative CTX effect on axillary lymph nodes. The
presence versus absence of axillary nodal metastases
remains the most powerful prognostic feature available
in stratifying breast cancer patients for risk of relapse.
Physical examination is notoriously inaccurate in pre-
dicting the status of axillary lymph nodes, and even the
most sophisticated soft tissue imaging modalities, such
as ultrasound, computerized tomography, and magnetic
resonance imaging, are unable to replace surgical resec-
tion and histopathologic examination.11 It was therefore
necessary for early studies of neoadjuvant CTX to ad-
dress the question of whether the CTX effect on axillary
lymph node metastases might eliminate valuable prog-
nostic information. McCready et al.,8 however, reported
on survival rates for 136 patients with locally advanced
breast cancer from the University of Texas M. D. Ander-
son Cancer Center, all of whom received induction doxo-
rubicin, fluorouracil, and cyclophosphamide before un-
dergoing modified radical mastectomy. These
investigators found that the extent of residual axillary
nodal metastases correlated well with outcome and was
an independent predictor of survival even after control-
ling for tumor stage at presentation, tumor grade, and
menopausal status.






Black 16/37 (43.2) .94
White 15/34 (44.1)
Tumor category at presentation
T3 9/33 (27.3) .009
T4 22/38 (57.9)
Nodal status at presentation









Positive 25/49 (50) .08
Negative 6/21 (28.6)
Pathologic response
Complete response 4/10 (40) .91
Partial response 23/53 (43.4)
No response 4/8 (50)
Histopathologic evidence of tumor
regression in axillary lymph
nodes
Present 6/19 (31.6) .19
Absent 25/51 (49)







No nodal metastases; no evidence of nodal
disease regression  axillary metastases
(n  12)
27% 31.5
Evidence of regression in axillary nodes;
metastases present (n  19)
32% 22.1
Axillary metastases present; no evidence
of nodal disease regression (n  39)
55% 19.8
DFS, disease-free survival.
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The promising results of surgical downstaging with
neoadjuvant CTX led to successful investigations of
breast-conservation therapy for patients with locally ad-
vanced breast cancer. Singletary et al.12 conducted a
feasibility study of breast-conserving therapy in a series
of locally advanced breast cancer patients treated with
preoperative CTX followed by mastectomy, and scrutiny
of the pathology specimens revealed that 23% of patients
had sufficient primary tumor shrinkage that a lumpec-
tomy could have been successfully performed. Other
studies have subsequently confirmed the oncological
safety of breast preservation in patients with locally
advanced breast cancer who are adequately downstaged
by preoperative CTX, and local recurrence rates are
comparable to those seen for lumpectomy in early-stage
breast cancer patients.13,14
The conceptual advantage of in vivo assessment of
primary tumor response to the selected CTX regimen is
another benefit derived from the neoadjuvant CTX ap-
proach. When systemic therapy is administered in the
postoperative setting, the patient and oncologist cannot
determine whether micrometastases are resistant to the
selected regimen until distant metastases become clini-
cally overt in long-term follow-up. Unfortunately, how-
ever, stage IV breast cancer is notoriously refractory to
successful treatment. Preoperative CTX allows the clini-
cian to evaluate the effectiveness of therapy within sev-
eral weeks as the initial one or two cycles of CTX are
administered. If the desired response is not seen, then
switching to a non–cross-resistant regimen may be con-
sidered. This approach may minimize exposing the pa-
tient to the cumulative toxicities of an ineffective
regimen.
Kuerer et al.15 confirmed the validity of tumor re-
sponse to induction CTX as a surrogate marker of treat-
ment effect on micrometastases in a survival study of
breast cancer patients with complete pathologic response
to doxorubicin-based preoperative CTX. Out of nearly
400 locally advanced breast cancer patients treated on
prospective treatment trials, 12% had no evidence of
residual invasive disease in their surgical specimens.
With a median follow-up of nearly 5 years, these com-
plete responders had a 5-year disease-free survival of
87%, compared with only 58% for those with less than a
complete response, and this difference in outcome was
statistically significant. As the armamentarium of CTX
combinations with effectiveness against breast tumors
expands, additional crossover regimens for patients with
resistant disease will be more readily available, and the
pool of complete responders should enlarge in parallel.
The advent of the taxanes, gemcitabine, and trastuzumab
(Herceptin; Genentech, South San Francisco, CA) is
quite promising in this regard.
Induction CTX and Early-Stage/Resectable
Breast Cancer
The excellent results of induction CTX for patients
with locally advanced breast cancer have led to applica-
tion of this approach to the setting of early-stage disease.
The National Surgical Adjuvant Breast Project (NSABP)
B-18 study2,3 has conclusively proven the safety of pre-
operative CTX in a prospective trial that randomized
patients with operable stage I to III disease to receive
preoperative versus postoperative CTX; it found overall
survival equivalence between the two arms of the study.
This study had striking similarities to the Kuerer et al.
report15; a complete pathologic response occurred in
13% of the patients receiving doxorubicin-based preop-
erative CTX, and disease-free survival was 85.7% for
this subset, which was significantly better than the sur-
vival rates of patients with a lesser response. Ongoing
trials through the NSABP and other institutions are eval-
uating combinations of doxorubicin, paclitaxel, do-
cetaxel, and vinorelbine in the preoperative setting for
patients with early-stage resectable breast cancer.
Induction CTX and Effect on Axillary Metastases
Clearly, there will be an increasing population of
patients with early-stage breast cancer who will be re-
ceiving systemic therapy before undergoing definitive
surgery. A more thorough pathologic assessment of treat-
ment effect on axillary lymph nodes is therefore war-
ranted as we attempt to integrate minimally invasive
approaches to axillary surgery into induction CTX algo-
rithms and as we attempt to identify patients who may
require additional CTX in the postoperative setting.
Currently, routine pathology practice is to perform
basic hematoxylin and eosin staining of axillary nodal
sections to identify viable metastases in patients with
breast cancer, regardless of whether or not preoperative
CTX has been delivered. The ability of neoadjuvant CTX
to successfully downstage the axilla has been conclu-
sively established, yet pathologic assessment of treat-
ment response after neoadjuvant CTX is not routinely
reported. Distinguishing patients who never had nodal
metastases from those who had disease successfully
eliminated by preoperative CTX is challenging, but it
may have prognostic value and therapeutic implications.
In the NSABP B-18 study,3 axillary nodal metastases
were found in 57% of patients randomized to receive
postoperative CTX, compared with only 41% of patients
receiving preoperative CTX (P  .001). Furthermore,
data from the M. D. Anderson Cancer Center4,7 have
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shown that among patients with fine-needle aspiration–
proven axillary nodal metastases at presentation, 23% to
30% will be completely node negative when axillary
nodal dissection is performed after induction CTX.
Preliminary data from studies of postoperative, adju-
vant CTX have indicated that patients with axillary nodal
metastases may benefit from receiving sequential doxo-
rubicin-based CTX and a taxane.16 Other investigators17
have reported that axillary nodal downstaging may be an
even more powerful prognostic feature than primary
breast tumor response in patients treated with preopera-
tive CTX. It may therefore be important in planning
therapeutic strategy to identify the patients who experi-
enced CTX-induced eradication of nodal metastases.
Outcome for these patients may be optimized by post-
operative delivery of additional CTX cycles and, possi-
bly, multiple-regimen therapies.
Another issue driving the importance of assessing
pathologic response to preoperative CTX in the axilla is
the increasingly popular technology of lymphatic map-
ping and sentinel lymph node biopsy. This minimally
invasive means of evaluating the axilla is an extremely
promising modality for accurately staging breast cancer
patients while avoiding the morbidity of a full axillary
lymph node dissection. However, the accuracy of senti-
nel lymph node biopsy in the setting of patients treated
with induction CTX is not yet fully understood, because
we do not know whether preoperative CTX will exert a
uniform effect on all axillary nodal metastases. False-
negative rates for sentinel lymph node biopsy in patients
receiving neoadjuvant CTX have been reported to range
from 0% to 33% in various studies,18–24 and identifica-
tion of the sentinel lymph node may be more difficult
because of the fibrotic reaction that may occur in axillary
soft tissues. Development of a standardized approach for
pathologically evaluating the CTX effect on axillary
nodes will be essential as lymphatic mapping becomes
incorporated into future preoperative CTX protocols.
Despite the numerous reported studies of neoadjuvant
CTX and the clear evidence that the extent of pathologic
response is a valid surrogate marker for chemosensitivity
in micrometastases, the pathologic assessment of treat-
ment response in breast and axillary tissue has not been
standardized. The presence versus the absence of treat-
ment effect within axillary lymph nodes may be partic-
ularly useful information. The ability to stratify preop-
eratively treated patients by node negativity versus
positivity, as well as by whether the nodes were down-
staged, may influence decisions regarding delivery of
additional postoperative CTX.
Our study demonstrated that specific patterns of
pathologic findings within the axillary lymph nodes of
patients receiving induction CTX are reliable indicators
of treatment response. These features include fibrosis
within lymph nodes, the presence of mucin pools, and
large aggregates of foamy histiocytes. As expected, strat-
ification of breast cancer patients receiving neoadjuvant
CTX into different categories on the basis of the pres-
ence versus absence of these features identified subsets
of patients with varying degrees of risk for disease re-
lapse. The patients with the best outcome were those
patients with no axillary metastases and no evidence of
treatment response. These patients were probably node
negative at time of diagnosis and probably had the lowest
burden of micrometastatic disease. At the other end of
the spectrum, patients with residual viable axillary me-
tastases had the worst outcome. These patients probably
had the most advanced disease at diagnosis and micro-
metastases that were at resistant to systemic treatment. In
the middle of the spectrum are the patients with or
without residual axillary metastases at the time of sur-
gery but who also show evidence of treatment response;
these patients had an outcome intermediate between the
completely node-negative patients and the node-positive
patients. This subset of patients probably had axillary
disease at time of diagnosis, but the disease was at least
partially responsive to the selected CTX regimen. These
patients probably have a greater micrometastatic burden
compared with the completely node-negative patients
without treatment effect. Conversely, the chemosensitiv-
ity of their disease defines them as a better prognostic
subset compared with patients with residual nodal me-
tastases and no treatment effect.
In summary, we believe that pathologic evaluation of
axillary lymph nodes in patients receiving preoperative
CTX should routinely include assessment of tumor re-
sponse patterns. This information may guide the clinician
regarding determination of CTX effectiveness and, more
importantly, may better identify patients with resistant
disease. This histopathologic response information may
also facilitate the interpretation of sentinel lymph node
biopsy in patients treated with induction CTX. Future
studies of induction CTX and histopathologic assessment
of the treatment effect in regional nodes, as well as
correlation with the number of CTX cycles required to
produce this effect, are warranted.
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